PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Propranolol Outperforms Oral Steroids for Infantile Haemangioma; Intralesional Steroids Remain Comparable

propranololcorticosteroidsprednisolonebetamethasonebeta-blockerinfantile haemangiomapediatric dermatologysystematic reviewmeta-analysisulcerationfirst-line therapy Pediatrics

Background Information

Propranolol outperforms corticosteroids in treating infantile haemangiomas.

Infantile haemangiomas are common vascular tumors in infants, and treatment choices can impact outcomes and safety. Propranolol had higher treatment effectiveness than corticosteroids (OR: 4.96) and fewer adverse events (OR: 0.27). Propranolol is more effective and safer than oral corticosteroids for IH, but intralesional corticosteroids may be considered based on lesion characteristics. Propranolol is favored over corticosteroids for infantile haemangiomas due to better efficacy and safety.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Sato A, Burns JWF, Sivanesan K, Haysom R, Riese D, Ghotra E, Chua KR, Lee SC, Nakanishi H, Than CA, Wong KY

Citation: Sato A, Burns JWF, Sivanesan K, et al. Comparative Outcomes of Propranolol and Corticosteroids in Infantile Haemangiomas: A Systematic Review and Meta-Analysis. British journal of hospital medicine (London, England : 2005). 2026;87(10):54357. doi:10.31083/BJHM54357

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.